Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (GlycoNex, Inc.), 地舒单抗生物类似药(GlycoNex, Inc.), SPD8 |
Target |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | TW | 01 Aug 2022 | |
Osteoporosis | Preclinical | TW | 01 Aug 2022 |